“How Do We Want to Live?” now Available in English

My popular science book “How Do We Want to Live?” is now available in English, both in print and as an ebook.

Stopping psychotropic drugs? Why, when and how?

My new book in German is now available: “Psychopharmaka absetzen? Warum, wann und wie?” (English “Stopping psychotropic drugs? Why, when and how?). The book is not a simple invitation to stop taking psychotropic drugs, but a critical examination of the topic.

How Do We Want To Live?

I’m happy to announce the imminent publication of my new book “Wie wollen wir leben?”. It’s on biological reductionism, psychiatry, and the creation of our future.

Prescribing Psychotropic Drugs? Join us in May in Mannheim!

The 14. Symposium of the task force Therapeutic Drug Monitoring of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) will be held between May 13 and 15, 2020, in Mannheim.

How do Psychotropic Drugs Work?

A video of my talk given at the Insight Conference in Berlin on Psychedelic Science on September 6th, 2019.

An Interview on the Foundations of Psychiatry

An interview for DasGehirn.Info on our understanding of psychopharmacology and its further development, about humanism and the political responsibility of psychiatry.

A Lecture on News in Psychopharmacology

My lecture on “Hot Topic: Psychopharmaka”, held in Mainz on March 15th, 2019, as part of the teaching event “Psychiatrie Update 2019”, was videotaped.

Insight 2019: Integrating Science and Practice of Psychedelic States

The Insight Conference 2019 on “Integrating Science and Practice of Psychedelic States” will take place in Berlin from September 5 – 7, 2019.

FDA Approves Esketamine for Treatment-Resistant Depression, While US Suicide Rate Reaches Record High

The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.

Esketamine for treatment-resistant depression submitted to FDA

Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.